# Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer

> **NCT07673211** · — · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Cervical Cancer
- Recurrent Cervical Cancer
- Metastatic Cervical Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Biospecimen collection (peripheral blood and paraffin tumor tissue)

## Key facts

- **NCT ID:** NCT07673211
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673211, "Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07673211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*